Avalo Therapeutics (AVTX) Non-Current Debt (2014 - 2023)

Avalo Therapeutics (AVTX) has 8 years of Non-Current Debt data on file, last reported at $10.5 million in Q1 2023.

• Quarterly Non-Current Debt fell 68.45% year-over-year to $10.5 million in Q1 2023, while the trailing twelve-month figure through Mar 2023 was $10.5 million (down 68.45% YoY) and the FY2022 annual result came in at $13.5 million, down 58.93% from the prior year.
• Non-Current Debt slipped to $10.5 million in Q1 2023, from $13.5 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $33.2 million in Q1 2022 to a low of $10.5 million in Q1 2023.
• A 4-year average of $19.8 million and a median of $16.5 million in 2022 frame the typical range for Non-Current Debt.
• Annual changes were most pronounced in 2022 — Non-Current Debt climbed 9.16% — and 2023, when it slumped 68.45%.
• Tracing AVTX's Non-Current Debt over 4 years: stood at $14.3 million in 2019, then soared by 130.33% to $32.8 million in 2021, then sank by 58.93% to $13.5 million in 2022, then decreased by 22.36% to $10.5 million in 2023.
• The last three Non-Current Debt figures came in at $10.5 million (Q1 2023), $13.5 million (Q4 2022), and $16.5 million (Q3 2022), per Business Quant data.